IL7 and cancer: Phase I/II studies of IL-7 immunotherapy in lymphodepleted cancer patients and HIV infected patients have demonstrated the capacity of this cytokine to reconstitute both the naive and memory CD4+ T cell pools and, importantly, to increase TCR repertoire diversity, which should help restore adaptive responses to diverse pathogens [50], [51].